Revenue Breakdown
Composition ()
No data
Revenue Streams
MannKind Corp (MNKD) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Product sales, accounting for 58.8% of total sales, equivalent to $48.27M. Other significant revenue streams include Royalties and Services. Understanding this composition is critical for investors evaluating how MNKD navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, MannKind Corp maintains a gross margin of 79.42%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 26.88%, while the net margin is 9.72%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively MNKD converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, MNKD competes directly with industry leaders such as ORKA and AGIO. With a market capitalization of $1.77B, it holds a leading position in the sector. When comparing efficiency, MNKD's gross margin of 79.42% stands against ORKA's N/A and AGIO's 86.96%. Such benchmarking helps identify whether MannKind Corp is trading at a premium or discount relative to its financial performance.
